Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QOLINPAC trial of nab-paclitaxel + gemcitabine versus gemcitabine in advanced pancreatic cancer
2013-004101-75Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jan 2014
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic cancer (PC) comparing nab-paclitaxel + gemcitabine with gemcitabine alone (2 arms). Primary endpoints: Deterioration-free rate at 3 months, Quality of life scores and 1 more. Started Jan 2014; status: completed.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2013-004101-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004101-75.